is complementary to a mature miRNA and interferes with the miRNA's appropriate binding to its natural targets. The affinity, average half-life, toxicity and/or delivery of these inhibitors have been improved through chemical modifications. The most popular chemical modifications are the substitution of phosphate bonds with phosphorothioate bonds, the methylation of the oxygen at position 2 in the ribose (2′-O-methyl), the addition of an extra bridge between the carbons of the ribose ring (locked nucleic acid or LNA), the substitution of the sugar backbone by a pseudopeptide backbone (peptide nucleic acid or PNA) or a morpholino ring (morpholino) and the attachment of a cholesterol at the 3′ OH end. These antisense technologies are used frequently in cell culture research, a setting where their deliveries are relatively simple. In addition, some studies have provided evidence of their successful use in experimental animals when they are administrated systemically 3, 4 .
Although miRNAs have some very unique properties, expression of miRNA genes incurs roughly the same challenges as that of protein-coding genes; like protein-coding genes, miRNAs and miRNA inhibitors can be expressed from plasmids. Naldini and colleagues take advantage of this to inhibit miRNAs in vivo without the use of synthetic anti-miRNA oligonucleotides. Using a lentiviral system, they have introduced a strongly expressed, decoy miRNA target into the genome to stably sequester mature miRNAs away from their natural targets 1 ( Fig. 1) . This work exploits two previously developed biotools: the generation of plasmids expressing artificial decoys that inhibit the desired miRNA's function by competing with its natural targets 5 and the superb ability of the lentivirus to introduce plasmids into the genome 6 , an area of expertise of the Naldini gene therapy group.
In their approach, the miRNA inhibitor is transcribed from a lentivirus vector and is expressed as an anti-miRNA decoy 1 (Fig. 1) . The integration of the miRNA inhibitor into a plasmid exploits a wealth of plasmid-based technology, which includes the use of reporters to track transient, stable or inducible expression and ern blot as biotools to help detect and quantify miRNAs. To complement these miRNA profiling assays, the scientific community has demanded tools to efficiently express or inhibit miRNAs to answer functional questions. Taking advantage of their small size and the current knowledge of miRNA biogenesis, modified RNAs can be transiently delivered as a synthetic, preprocessed miRNA or anti-miRNA oligonucleotides. Not only are these biotools interesting for gain-or loss-of-function assays, they are also useful for therapeutics, as the aberrant metabolism or expression of miRNAs has been linked to human diseases including cancer 2 .
Transient inhibition of specific miRNAs takes advantage of antisense technology that emerged before the discovery of the miRNAs. An anti-miRNA oligonucleotide MicroRNAs (miRNAs) are a class of small RNA molecules, about 22 nucleotides long that regulate gene expression post-transcriptionally, by binding to partially complementary sequences in downstream target mRNAs. Because they were only discovered just over a decade ago, new technologies to study the unique properties of miRNAs are still needed. In this issue Luigi Naldini and colleagues present techniques to manipulate miRNA expression by expressing decoy miRNA targets via lentiviral vectors 1 .
Some of the challenges unique to studying miRNAs include finding techniques to detect their presence and methods that allow functional studies. Specific quantitative PCR and high-throughput profiling techniques (such as miRNA microarrays and bead-based miRNA profiling) have joined the traditional, but robust, northinhibiting microrna function in vivo
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A new strategy is presented to functionally knock down microRNAs in a mouse. ine the let-7 microRNA familya large, well-known tumor suppressor miRNA family 10 to provide clues as to the functional consequence of knocking down all let-7 miRNAs. Now that this ability to perform loss-offunction assays has been validated in vivo, this will undoubtedly help us shed light on the functional roles of miRNAs.
